References

Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood antic-oagulated with bivalirudin or enoxaparin compared with unfractionated heparin: implications for coronary intervention. J Thromb Thrombolysis 13:161-165, 2002.

Ahmad S, Jeske WP, Walenga JM, Hoppensteadt DA, Wood JJ, Herbert JM, Messmore HL, Fareed J. Synthetic pentasaccharides do not cause platelet activation by anti-heparin-platelet factor 4 antibodies. Clin Appl Thromb Hemost 5:259-266, 1999.

Amiral J, Bridey F, Dreyfus M, Vissac AM, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95-96, 1992.

Amiral J, Bridey F, Wolf M, Boyer-Neumann C, Fressinaud E, Vissac AM, Peynaud-Debayle E, Dreyfus M, Meyer D. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost 73:21-28, 1995.

Amiral J, Peynaud-Debayle E, Wolf M, Bridey F, Vissac AM, Meyer D. Generation of antibodies to heparin-PF4 complexes without thrombocytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol 52:90-95, 1996.

Balduini CL, Noris P, Bertolino G, Previtali M. Heparin modifies platelet count and function in patients who have undergone thrombolytic therapy for acute myocardial infarction [letter]. Thromb Haemost 69:522-523, 1993.

Barber AF, Kaser-Glanzmann R, Jakabova M, Luscher EF. Characterization of a chondroitin 4-sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochim Biophys Acta 286:312-329, 1972.

Berglund U, Wallentin L. Influence on platelet function by heparin in men with unstable coronary artery disease. Thromb Haemost 66:648-651, 1991.

Bock PE, Luscombe M, Marshall SE, Pepper DS, Holbrook JJ. The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J 191:769-776, 1980.

Borowska A, Lauri D, Maggi A, Dejana E, de Gaetano G, Donati MB, Pangrazzi J. Impairment of primary haemostasis by low molecular weight heparins in rats. Br J Haematol 68:339-344, 1988.

Boshkov LK, Warkentin TE, Hayward CPM, Andrew M, Kelton JG. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 84:322-328, 1993.

Brace LD, Fareed J. Heparin-induced platelet aggregation. II. Dose/response relationships for two low molecular weight heparin fractions (CY216 and CY222). Thromb Res 59:1-14, 1990.

Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfrac-tionated heparin, low molecular weight heparin and heparinoid in intensive care patients and healthy controls. Eur J Haematol 58:279-285, 1997.

Capitanio AM, Niewiarowski S, Rucinski B, Tuszynski GP, Cierniewski CS, Hershock D, Kornecki E. Interaction of platelet factor 4 with human platelets. Biochim Biophys Acta 839:161-173, 1985.

Carter CJ, Kelton JG, Hirsh J, Cerskus A, Santos AV, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59:1239-1245, 1982.

Casu B, Petitou M, Provasoli M, Sinay P. Conformational flexibility: a new concept for explaining binding and biological properties of iduronic acid-containing glycosami-noglycans. Trends Biochem Sci 13:221-225, 1988.

Chen J, Sylven C. Heparin potentiation of collagen-induced platelet aggregation is related to the GPIIb/GPIIIa receptor and not to the GPIb receptor, as tested by whole blood aggregometry. Thromb Res 66:111-120, 1992.

Chen J, Karlberg KE, Sylven C. Heparin enhances platelet aggregation irrespective of anticoagulation with citrate or with hirudin. Thromb Res 67:253-262,1992.

Chong BH. Heparin-induced thrombocytopenia. Blood Rev 2:108-114, 1988.

Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis and platelet aggregation. Lancet ii:1246-1248,1982.

Chong BH, Ismail F. The mechanism of heparin-induced platelet aggregation. Eur J Haematol 43:245-251,1989.

Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 316:581-589, 1987.

Cofrancesco E, Colombi M, Manfreda M, Pogliani EM. Effect of heparin and related glycosaminoglycans (GAGs) on thrombin-induced platelet aggregation and release. Haematologica 73:471-475, 1988.

Davey MG, Lander H. Effect of injected heparin on platelet levels in man. J Clin Pathol 21:55-59, 1968.

Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet factor 4 by heparin. Thromb Res 27:65-76, 1982.

Eika C. The platelet aggregating effect of eight commercial heparins. Scand J Haematol 9:480-482,1972.

Elalamy I, Lecrubier C, Potevin F, Abdelouahed M, Bara L, Marie JP, Samama MM. Absence of in vitro cross-reaction of pentasaccharide with the plasma heparin-dependent factor of twenty-five patients with heparin-associated thrombocytopenia. Thromb Haemost 74:1379-1387,1995.

Eldor A, Weksler BB. Heparin and dextran sulfate antagonize PGI2 inhibition of platelet aggregation. Thromb Res 16:617-628,1979.

Fernandez F, N'guyen P, Van Ryn J, Ofosu FA, Hirsh J, Buchanan MR. Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defect. Thromb Res 43:491-495, 1986.

Fortini A, Modesti PA, Abbate R, Gensini GF, Neri Serneri GG. Heparin does not interfere with prostacyclin and prostaglandin D2 binding to platelets. Thromb Res 40:319-328, 1985.

Gollub S, Ulin AW. Heparin-induced thrombocytopenia in man. J Lab Clin Med 59:430-435, 1962.

Greinacher A, Michels I, Liebenhoff U, Presek P, Mueller-Eckhardt C. Heparin-asso-ciated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br J Haematol 84: 711-716,1993.

Greinacher A, Gopinadhan M, Gunther J-U, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 26:2386-2393, 2006.

Heiden D, Mielke CH, Rodvien R. Impairment by heparin of primary haemostasis and platelet [14C]-5-hydroxytryptamine release. Br J Haematol 36:427-436,1977.

Heinrich D, Görg T, Schulz M. Effects of unfractionated and fractionated heparin on platelet function. Haemostasis 18:(suppl 3) 48-54, 1988.

Herbert J-M, Savi P, Jeske WP, Walenga JM. Effect of SR121566A, a potent GP IIb-IIIa antagonist, on the HIT serum/heparin-induced platelet mediated activation of human endothelial cells. Thromb Haemost 80:326-331, 1998.

Hirsh J. Heparin induced bleeding. Nouv Rev Fr Hematol 26:261-266, 1984.

Hjort PF, Borchgrevink CF, Iversen OH, Stormorken H. The effect of heparin on the bleeding time. Thromb Diath Haemorrh 4:389-399, 1960.

Holmer E, Lindahl U, Backstrom G, Thunberg L, Sandberg H, Söderström G, Andersson L-O. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 18:861-869, 1980.

Horne MK III. Heparin binding to normal and abnormal platelets. Thromb Res 51: 135-144, 1988.

Horne MK III. Heparin binds normally to platelets digested with Streptomyces griseus protease. Thromb Res 61:155-158, 1991.

Horne MK III. The effect of secreted heparin-binding proteins on heparin binding to platelets. Thromb Res 70:91-98,1993.

Horne MK III, Chao ES. Heparin binding to resting and activated platelets. Blood 74:238-243, 1989.

Horne MK III, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 74:306-312, 1990.

Horne MK III, Alkins BR. Platelet binding of IgG from patients with heparin-induced thrombocytopenia. J Lab Clin Med 127:435-442, 1996.

Horne MK III, Hutchison KJ. Simultaneous binding of heparin and platelet factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am J Hematol 58:24-30,1998.

John LCH, Rees GM, Kovacs IB. Inhibition of platelet function by heparin. J Thorac Cardiovasc Surg 105:816-822, 1993.

Johnson RA, Lazarus KH, Henry DH. Heparin-induced thrombocytopenia: a prospective study. Am J Hematol 17:349-353, 1984.

Kappers-Klunne MC, Boon DMS, Hop WCJ, Michiels JJ, Stibbe J, van der Zwaan C, Koudstaal PJ, van Vliet HHDM. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascu-lar diseases. Br J Haematol 96:442-446, 1997.

Kelton JG, Smith JW, Warkentin TE, Hayward CPM, Denomme GA, Horsewood P. Immunoglobin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232-3239, 1994.

Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birjiniuk V, Oimet H, Pasche B, Nelson MJ, Benoit SE, Rodino LJ, Barnard MR, Michelson AD. The platelet function defect of cardiopulmonary bypass. Blood 82:107-117,1993.

Klein B, Faridi A, von Tempelhoff GH, Heilmann L, Mittermayer C, Rath W. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res 108:291-296, 2002.

Lindahl U, Kjellen L. Heparin or heparan sulfate - what is the difference? Thromb Haemost 66:44-48,1991.

Loscalzo J, Melnick B, Handin RI. The interaction of platelet factor four and glycosami-noglycans. Arch Biochem Biophys 240:446-455,1985.

Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 70:554-561, 1993.

Mikhailidis DP, Barradas MA, Jeremy JY, Gracey L, Wakeling A, Dandona P. Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur J Clin Invest 15:313-319,1985.

Newman PM, Chong BH. Further characterization of antibody and antigen in heparin-induced thrombocytopenia. Br J Haematol 107:303-309, 1999.

Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb Haemost 80:292-297, 1998.

O'Brien JR, Etherington MD, Pashley MA. Intra-platelet platelet factor 4 (IP.PF4) and the heparin-mobilisable pool of PF4 in health and atherosclerosis. Thromb Haemost 51:354-357, 1984.

O'Brien JR, Etherington MD, Pashley MA. The heparin-mobilisable pool of platelet factor 4: a comparison of intravenous and subcutaneous heparin and Kabi heparin fragment 2165. Thromb Haemost 54:735-738, 1985.

Ockelford PA, Carter CJ, Cerskus A, Smith CA, Hirsh J. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction. Thromb Res 27:679-690, 1982.

Rao AK, Niewiarowski S, James P, Holt JC, Harris M, Elfenbein B, Bastl C. Effect of heparin on the in vivo release and clearance of human platelet factor 4. Blood 61:1208-1214, 1983.

Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS. Ultra large complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131-138, 2005.

Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M. Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogen-esis: diagnostic and therapeutic implications. Blood 107:2346-2353, 2006.

Reininger CB, Greinacher A, Graf J, Lasser R, Steckmeier B, Schweiberer L. Platelets of patients with peripheral arterial disease are hypersensitive to heparin. Thromb Res 81:641-649, 1996.

Saba HI, Saba SR, Blackburn CA, Hartmann RC, Mason RG. Heparin neutralization of PGI2: effects upon platelets. Science 205:499-501, 1979.

Saba HI, Saba SR, Morelli GA. Effect of heparin on platelet aggregation. Am J Hematol 17:295-306, 1984.

Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 65:64-73,1980.

Sappington SW. The use of heparin in blood transfusions. JAMA 113:22-25,1939.

Slocum MM, Adams JG, Teel R, Spadone DP, Silver D. Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome. J Vasc Surg 23:839-843, 1996.

Sobel M, Adelman B. Characterization of platelet binding of heparins and other glycosaminoglycans. Thromb Res 50:815-826, 1988.

Sobel M, McNeil PM, Carlson PL, Kermode JC, Adelman B, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 87:1787-1793, 1991.

Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 267:8857-8862, 1992.

Sobel M, Fish WR, Toma N, Luo S, Bird K, Mori K, Kusumoto S, Blystone SD, Suda Y. Heparin modulates integrin function in human platelets. J Vasc Surg 33:587-594, 2001.

Tiffany ML, Penner JA. Heparin and other sulfated polyanions: their interaction with the blood platelet. Ann NY Acad Sci 370:662-667, 1981.

Van Ryn-McKenna J, Ofosu FA, Hirsh J, Buchanan MR. Antithrombotic and bleeding effects of glycosaminoglycans with different degrees of sulfation. Br J Haematol 71:265-269, 1989.

Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 93:81-88, 1994.

Visentin GP, Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 128:376-383, 1996.

Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacolo-gic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 86:1-36, 1997.

Ware AJ, Coller BS. Platelet morphology, biochemistry, and function. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology, fifth edition. New York: McGraw-Hill, 1161-1201, 1995.

Warkentin TE, Kelton JG. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H, ed. Low-Molecular-Weight Hepar-ins in Prophylaxis and Therapy of Thromboembolic Diseases. New York: Marcel Dekker, 75-127, 1994.

Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330-1335, 1995.

Warkentin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79:1-7, 1998.

Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96:1703-1708, 2000.

Warkentin TE, Cook RJ, Marder VJ, Sheppard JI, Moore JC, Eriksson BI, Greinacher A, Kelton JG. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106:3791-3796, 2005.

Westwick J, Scully MF, Poll C, Kakkar VV. Comparison of the effects of low molecular weight heparin and unfractionated heparin on activation of human platelets in vitro. Thromb Res 42:435-447, 1986.

Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 97:251-256, 1998.

Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractio-nated heparin. Thromb Haemost 71:300-304, 1994.

Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook


Post a comment